Democratic presidential candidate Joe Biden speaks at a drive-in rally in Miramar, Florida on October 13, 2020. (Photo by JIM WATSON/AFP via Getty Images)

Democratic presidential candidate Joe Biden speaks at a drive-in rally in Miramar, Florida on October 13, 2020. (Photo by JIM WATSON/AFP via Getty Images)

(CNSNews.com) – Democrat Joe Biden and his fellow Democrats rail against President Trump and Republicans for wanting to get rid of the Affordable Care Act, with its high premiums and co-pays and limited options for millions of Americans.

But even Biden isn’t satisfied with the law as it now stands.

At a campaign stop in Miramar, Florida on Tuesday, Biden urged a larger role for government in Americans’ health insurance coverage, including bigger subsidies and expanded Medicaid/Medicare:

“Together, we’ll build on the Affordable Care Act by adding–by adding a new health insurance option, a not-for-profit option, to give private insurers a real competitor,” Biden said.

“We’ll increase (government) subsidies so premiums are lower cost to get more coverage, lower deductibles, lower out-of-pocket expenses.

“And by the way, anybody, anybody who qualifies for Medicare, but lives in a state like your governor that doesn’t allow for 800,000 people to have it, will automatically be enrolled. It’s wrong.”

Biden meant “anyone who qualifies for Medicaid”; Florida has not expanded Medicaid under the Affordable Care Act. But Biden also could have been thinking about Medicare for all, which has always been the goal of Democrats.

According to the Biden-Sanders Unity Task Force Recommendations, Democrats will secure universal health care through a public option, as follows:

Private insurers need real competition to ensure they have incentive to provide affordable, quality coverage to every American. To achieve that objective, we will give all Americans the choice to select a high-quality, affordable public option through the Affordable Care Act marketplace.

The public option will provide at least one plan choice without deductibles, will be administered by the traditional Medicare program, not private

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the closing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at an effective offering price of $3.10 per share of common stock. In addition, the Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock.


(PRNewsfoto/Benitec Biopharma Inc.)

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The gross proceeds from this offering to the Company are approximately $11.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for the continued advancement of development activities for its product pipeline, general corporate purposes, and strategic growth opportunities.

A registration statement on Form S-1 (File No. 333-246314) relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC“) on October 2, 2020. This offering is being made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to and describing the terms of the offering has been filed with the SEC. Electronic copies of the final prospectus relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer

DENVER, Oct. 6, 2020 /PRNewswire/ — Hycroft Mining Holding Corporation (Nasdaq: HYMC) (“Hycroft” or the “Company”), today announced the closing of its previously announced public offering (the “Offering”) of 9,583,334 units (which includes the exercise in full of the underwriters’ option to purchase 1,250,000 additional units) at a price to the public of $9.00 per unit.  The Offering was upsized from the initial offering of 7,220,000 units (not including the underwriters’ initial over-allotment option of 1,083,000 units). Each unit issued in the Offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $10.50 per share. The warrants are immediately exercisable and expire five years from the date of issuance. The Company does not plan to apply to list the warrants on The Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system. The shares of common stock and warrants are immediately separable and were issued separately in the Offering.

(PRNewsfoto/Hycroft Mining Holding Corporat)
(PRNewsfoto/Hycroft Mining Holding Corporat)

After deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, the net proceeds to the Company were approximately $83.1 million.

Diane Garrett, Hycroft’s President and CEO commented “we are very pleased with the success of this financing which allows us to continue advancing the Hycroft Mine and unlocking the value of this significant mineral endowment.  This financing also demonstrates the continued support of our existing shareholders and we welcome the many new shareholders who also participated.”

David Kirsch, Chairman of the Board, said “Hycroft has always been one of the largest gold and silver deposits in the world, and now coupled with Diane’s leadership and the proceeds of this financing, we believe Hycroft is well positioned for success as it continues